Therefore, this study aimed to perform a systematic review and meta-analysis to comprehensively compare subcutaneous and intravenous trastuzumab in HER2-positive breast cancer regarding efficacy, safety, and patient preference. The gene discussed is ERBB2; the disease is breast carcinoma.